

Redaction #	Document Title	Bates Stamp	Reasons for Redaction	Statutory Basis	Partially or Entirely Redacted?
1	Attachment IV.10.b – Party A – Bylaws	HCMO-SUPP-000007 - HCMO-SUPP-000014	CenterWell requests confidential treatment of governance documents. As a nonpublic entity, these documents have not been made publicly available in any other forum. Further, this information is competitively sensitive, and disclosure would cause commercial harm to CenterWell. (See ORS 192.345(2)). Under ORS 415.501(13)(c), the Oregon Health Authority is prohibited from disclosing any confidential information and documents that are not publicly available that are obtained in relation to a “material change transaction.” As such, CenterWell is requesting further confidential treatment of these materials. **Party A is providing this material in a separate submission in order to keep such information confidential and protected from Party B and Party C.	ORS 192.345(2); ORS 415.501(13)(c)	Entirely Redacted
2	Attachment IV.11.e. – Party B and Party C – Financial Statements	HCMO-SUPP-000423 - HCMO-SUPP-000429	Hy-Vee requests confidential treatment of the submitted financial statements. As a nonpublic entity, this information has not been made publicly available in any other forum. Further, this information is competitively sensitive, and disclosure would enable competitors to identify and exploit potential vulnerabilities in Hy-Vee’s operating model (See ORS 192.345(2)). Under ORS 415.501(13)(c), the Oregon Health Authority is prohibited from disclosing any confidential information and documents that are not publicly available that are obtained in relation to a “material change transaction.” As such, Hy-Vee requests confidential treatment of its financial statements, unless Hy-Vee provides written consent of publication. **Party B and Party C are providing this material in a separate submission in order to keep such information confidential and protected from Party A	ORS 192.345(2); ORS 415.501(13)(c)	Entirely Redacted
4	Equity Purchase Agreement	HCMO-SUPP-000028 - HCMO-SUPP-000348	The parties request confidential treatment of the Equity Purchase Agreement between the parties. The agreement has not been made public, and contains confidential information, and disclosure would cause commercial harm to the parties. (See ORS 192.345(2)). Under ORS 415.501(13)(c), the Oregon Health Authority is prohibited from disclosing any confidential information and documents that are not publicly available that are obtained in relation to a “material change transaction.” As such, the parties are requesting further confidential treatment of these materials.	ORS 192.345(2); ORS 415.501(13)(c)	Entirely Redacted

6	Party B – Governance Documents	HCMO-SUPP-000433 - HCMO-SUPP-000484	Hy-Vee requests confidential treatment of governance documents related to Hy-Vee, HYVACS, Amber Acquisition, and Amber Enterprises (other than information that is publicly available). As a nonpublic entity, this information has not been made publicly available in any other forum. Further, this information is competitively sensitive, and disclosure would enable competitors to identify and exploit potential vulnerabilities in Hy-Vee’s operating model (See ORS 192.345(2)). Under ORS 415.501(13)(c), the Oregon Health Authority is prohibited from disclosing any confidential information and documents that are not publicly available that are obtained in relation to a “material change transaction.” As such, Hy-Vee requests confidential treatment of its governance documents, unless Hy-Vee provides written consent of publication. **Party B is providing this material in a separate submission in order to keep such	ORS 192.345(2); ORS 415.501(13)(c)	Partially Redacted
7	Party C – Governance Documents	HCMO-SUPP-000485 - HCMO-SUPP-000523	Hy-Vee requests confidential treatment of governance documents related to Hy-Vee, HYVACS, Amber Acquisition, and Amber Enterprises (other than information that is publicly available). As a nonpublic entity, this information has not been made publicly available in any other forum. Further, this information is competitively sensitive, and disclosure would enable competitors to identify and exploit potential vulnerabilities in Hy-Vee’s operating model (See ORS 192.345(2)). Under ORS 415.501(13)(c), the Oregon Health Authority is prohibited from disclosing any confidential information and documents that are not publicly available that are obtained in relation to a “material change transaction.” As such, Hy-Vee requests confidential treatment of its governance documents, unless Hy-Vee provides written consent of publication. **Party C is providing this material in a separate submission in order to keep such	ORS 192.345(2); ORS 415.501(13)(c)	Partially Redacted
8	Diligence Report	HCMO-SUPP-000355 - HCMO-SUPP-000422	CenterWell requests confidential treatment of this diligence report. As a nonpublic entity, these documents have not been made publicly available in any other forum. Further, this information is competitively sensitive, and disclosure would cause commercial harm to CenterWell. (See ORS 192.345(2)). Under ORS 415.501(13)(c), the Oregon Health Authority is prohibited from disclosing any confidential information and documents that are not publicly available that are obtained in relation to a “material change transaction.” As such, CenterWell is requesting further confidential treatment of these materials. **Party A is providing this material in a separate submission in order to keep such information confidential and protected from Party B and Party C.	ORS 192.345(2); ORS 415.501(13)(c)	Entirely Redacted